SWOG clinical trial number
S1900BDSS
S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS VCP)
Open
Abbreviated Title
S1900BDSS Version Control Protocol
Status Notes
The LUNGMAP S1900 Biomarker-Driven Sub-Study Version Control Protocol (S1900BDSS) is active effective 1/28/19.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
The intent of the S1900BDSS is to allow an individual sub-study to be revised independently of the other sub-studies. The S1900BDSS keeps track of revisions made to various S1900 biomarker-driven sub-studies of LUNGMAP and their component documents over the course of the overarching Lung-MAP study, and lists the version date of each revision.
Sites may use this document to verify the most current version of a LUNGMAP S1900 biomarker-driven sub-study, and may also reference this document for an overview of S1900 sub-study revisions.
Activated
01/28/2019
Research committees
LungMAP
Other Clinical Trials
SWOG Clinical Trial Number
S1800E
A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Research Committee(s)
LungMAP
Activated
04/28/2025
Accrual
10%
Open
Phase
SWOG Clinical Trial Number
S1900J
A Phase II Study of Amivantamab SC (subcutaneous) in Participants Previously Treated with High MET-Amplification for Stage IV or Recurrent Non-Small-Cell Lung Cancer (Lung-MAP Sub-Study)
Research Committee(s)
LungMAP
Activated
09/27/2024
Accrual
3%
Open
Phase
SWOG Clinical Trial Number
S1900K
A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Research Committee(s)
LungMAP
Activated
12/18/2023
Accrual
29%
Open
Phase